{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:26:23Z","timestamp":1787765183466,"version":"build-2784847793"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s13318-024-00921-4","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T10:02:20Z","timestamp":1729850540000},"page":"733-750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Assessment of Abuse Liability and Nicotine Pharmacokinetics of glo Heated Tobacco Products in a Randomized, Crossover Study"],"prefix":"10.1007","volume":"49","clinical-trial-number":[{"clinical-trial-number":"nct05114863","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2259-5481","authenticated-orcid":false,"given":"Milly N.","family":"Kanobe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7199-0628","authenticated-orcid":false,"given":"Patrudu","family":"Makena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1457-3561","authenticated-orcid":false,"given":"Kristen","family":"Prevette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9473-9719","authenticated-orcid":false,"given":"Sarah A.","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"921_CR1","unstructured":"U.S. Department of Health and Human Services, The health consequences of smoking \u2013 50 years of progress: a report of the Surgeon General. 2014, Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. 1-386"},{"key":"921_CR2","unstructured":"Centers for Disease Control and Prevention, Publications and Reports of the Surgeon General. How Tobacco Smoke Causes Disease: The biology and behavioral basis for smoking-attributable disease: a report of the surgeon general. 2010, Atlanta (GA): Centers for Disease Control and Prevention (US)"},{"key":"921_CR3","unstructured":"Institute of Medicine 2001, Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction. 2001, Washington, DC: The National Academies Press."},{"issue":"52","key":"921_CR4","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.15585\/mmwr.mm6552a1","volume":"65","author":"S Babb","year":"2017","unstructured":"Babb S, et al. Quitting smoking among adults - United States, 2000\u20132015. MMWR Morb Mortal Wkly Rep. 2017;65(52):1457\u201364.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"921_CR5","unstructured":"Centers for disease control and prevention, smoking cessation: Fast Facts. 2023."},{"issue":"5","key":"921_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40265-013-0038-y","volume":"73","author":"MJ Carpenter","year":"2013","unstructured":"Carpenter MJ, et al. Clinical strategies to enhance the efficacy of nicotine replacement therapy for smoking cessation: a review of the literature. Drugs. 2013;73(5):407\u201326.","journal-title":"Drugs"},{"key":"921_CR7","first-page":"Cd000146","volume":"11","author":"LF Stead","year":"2012","unstructured":"Stead LF, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:Cd000146.","journal-title":"Cochrane Database Syst Rev"},{"key":"921_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1146\/annurev-publhealth-040617-013849","volume":"39","author":"DB Abrams","year":"2018","unstructured":"Abrams DB, et al. Harm minimization and tobacco control: reframing societal views of nicotine use to rapidly save lives. Annu Rev Public Health. 2018;39:193\u2013213.","journal-title":"Annu Rev Public Health"},{"issue":"4","key":"921_CR9","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1136\/tc.2008.027318","volume":"18","author":"M Zeller","year":"2009","unstructured":"Zeller M, Hatsukami D. The strategic dialogue on tobacco harm reduction: a vision and blueprint for action in the US. Tob Control. 2009;18(4):324\u201332.","journal-title":"Tob Control"},{"key":"921_CR10","unstructured":"U.S. Department of Health and Human services, smoking cessation: a report of the surgeon general. 2020."},{"key":"921_CR11","unstructured":"Rodgman A, Perfetti TA. The chemical components of tobacco and tobacco smoke. 2nd ed. 2013, Boca Raton, FL: CRC Press."},{"key":"921_CR12","unstructured":"Food and drug administration, harmful and potentially harmful constituents in tobacco products and tobacco smoke; Established List, U.S. Department of Health and Human Services, Editor. 2012: Federal Register. p. 20034-20037."},{"issue":"9","key":"921_CR13","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/ntr\/ntp104","volume":"11","author":"RP Murray","year":"2009","unstructured":"Murray RP, Connett JE, Zapawa LM. Does nicotine replacement therapy cause cancer? Evidence from the lung health study. Nicotine Tob Res. 2009;11(9):1076\u201382.","journal-title":"Nicotine Tob Res"},{"issue":"2","key":"921_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1212\/WNL.0b013e31823efcbb","volume":"78","author":"P Newhouse","year":"2012","unstructured":"Newhouse P, et al. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology. 2012;78(2):91\u2013101.","journal-title":"Neurology"},{"issue":"4","key":"921_CR15","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1136\/tc.2008.027318","volume":"18","author":"M Zeller","year":"2009","unstructured":"Zeller M, Hatsukami D. Strategic dialogue on tobacco harm reduction, the strategic dialogue on tobacco harm reduction: a vision and blueprint for action in the US. Tob Control. 2009;18(4):324\u201332.","journal-title":"Tob Control"},{"key":"921_CR16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3389\/fpubh.2019.00287","volume":"7","author":"N Mallock","year":"2019","unstructured":"Mallock N, et al. Heated tobacco products: a review of current knowledge and initial assessments. Front Public Health. 2019;7:287.","journal-title":"Front Public Health"},{"key":"921_CR17","unstructured":"Centers for Diseases Control and Prevention. Heated Tobacco Products. 2023. Available from: https:\/\/www.cdc.gov\/tobacco\/basic_information\/heated-tobacco-products\/. Accessed 31 May 2023."},{"key":"921_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.yrtph.2017.10.006","volume":"93","author":"M Forster","year":"2018","unstructured":"Forster M, et al. Assessment of novel tobacco heating product THP1.0. Part 3: Comprehensive chemical characterisation of harmful and potentially harmful aerosol emissions. Regul Toxicol Pharmacol. 2018;93:14\u201333.","journal-title":"Regul Toxicol Pharmacol"},{"key":"921_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.yrtph.2018.09.016","volume":"99","author":"H Gasparyan","year":"2018","unstructured":"Gasparyan H, et al. Accurate measurement of main aerosol constituents from heated tobacco products (HTPs): Implications for a fundamentally different aerosol. Regul Toxicol Pharmacol. 2018;99:131\u201341.","journal-title":"Regul Toxicol Pharmacol"},{"key":"921_CR20","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.toxrep.2022.06.014","volume":"9","author":"S Goodall","year":"2022","unstructured":"Goodall S, et al. Evaluation of behavioural, chemical, toxicological and clinical studies of a tobacco heated product glo\u2122 and the potential for bridging from a foundational dataset to new product iterations. Toxicol Rep. 2022;9:1426\u201342.","journal-title":"Toxicol Rep"},{"key":"921_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2024.153801","volume":"504","author":"BM Keyser","year":"2024","unstructured":"Keyser BM, et al. In vitro toxicological evaluation of glo menthol and non-menthol heated tobacco products. Toxicology. 2024;504: 153801.","journal-title":"Toxicology"},{"key":"921_CR22","first-page":"111","volume":"2009","author":"United States Congress","year":"2009","unstructured":"United States Congress. Family smoking prevention and tobacco control and federal retirement reform. Public Law. 2009;2009:111\u201331.","journal-title":"Public Law"},{"key":"921_CR23","unstructured":"Food and Drug Administration Premarket Tobacco Product Applications and Recordkeeping Requirements. 2021."},{"issue":"12","key":"921_CR24","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1158\/1055-9965.EPI-09-0948","volume":"18","author":"LP Carter","year":"2009","unstructured":"Carter LP, et al. Abuse liability assessment of tobacco products including potential reduced exposure products. Cancer Epidemiol Biomarkers Prev. 2009;18(12):3241\u201362.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"13","key":"921_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2010.12.009","volume":"116","author":"JE Henningfield","year":"2011","unstructured":"Henningfield JE, et al. Conference on abuse liability and appeal of tobacco products: conclusions and recommendations. Drug Alcohol Depend. 2011;116(13):1\u20137.","journal-title":"Drug Alcohol Depend"},{"key":"921_CR26","doi-asserted-by":"crossref","unstructured":"Fearon IM. Human abuse liability assessment of e-cigarettes: Why, what and how? Drug Test Anal, 2022.","DOI":"10.1002\/dta.3251"},{"issue":"3","key":"921_CR27","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/ntr\/ntab183","volume":"24","author":"A Vansickel","year":"2022","unstructured":"Vansickel A, et al. Human abuse liability assessment of tobacco and nicotine products: approaches for meeting current regulatory recommendations. Nicotine Tob Res. 2022;24(3):295\u2013305.","journal-title":"Nicotine Tob Res"},{"key":"921_CR28","unstructured":"Food and Drug Administration, Assessment of Abuse Potential of Drugs. Guidance for Industry, U.S. Department of Health and Human Services, Editor. 2017: Silver Spring MD"},{"issue":"1","key":"921_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0376-8716(93)90041-N","volume":"34","author":"SJ Heishman","year":"1993","unstructured":"Heishman SJ, Snyder FR, Henningfield JE. Performance, subjective, and physiological effects of nicotine in non-smokers. Drug Alcohol Depend. 1993;34(1):11\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"921_CR30","doi-asserted-by":"publisher","first-page":"14701","DOI":"10.1038\/s41598-022-19167-8","volume":"12","author":"G Hardie","year":"2022","unstructured":"Hardie G, et al. An abuse liability assessment of the glo tobacco heating product in comparison to combustible cigarettes and nicotine replacement therapy. Sci Rep. 2022;12(1):14701.","journal-title":"Sci Rep"},{"issue":"4","key":"921_CR31","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/ntr\/ntz013","volume":"22","author":"C Haziza","year":"2020","unstructured":"Haziza C, et al. Reduction in exposure to selected harmful and potentially harmful constituents approaching those observed upon smoking abstinence in smokers switching to the menthol tobacco heating system 2.2 for 3 Months (Part 1). Nicotine Tob Res. 2020;22(4):539\u201348.","journal-title":"Nicotine Tob Res"},{"key":"921_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-3-540-69248-5_2","volume":"192","author":"NL Benowitz","year":"2009","unstructured":"Benowitz NL, Hukkanen J, Jacob P 3rd. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol. 2009;192:29\u201360.","journal-title":"Handb Exp Pharmacol"},{"issue":"5","key":"921_CR33","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1037\/0022-006X.61.5.743","volume":"61","author":"JE Henningfield","year":"1993","unstructured":"Henningfield JE, Keenan RM. Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol. 1993;61(5):743\u201350.","journal-title":"J Consult Clin Psychol"},{"issue":"3","key":"921_CR34","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/cpdd.909","volume":"10","author":"J Liu","year":"2021","unstructured":"Liu J, et al. Characterization of the abuse potential in adult smokers of a novel oral tobacco product relative to combustible cigarettes and nicotine polacrilex gum. Clin Pharmacol Drug Dev. 2021;10(3):241\u201350.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"921_CR35","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ypmed.2018.06.010","volume":"117","author":"DB Abrams","year":"2018","unstructured":"Abrams DB, et al. Managing nicotine without smoke to save lives now: evidence for harm minimization. Prev Med. 2018;117:88\u201397.","journal-title":"Prev Med"},{"issue":"9","key":"921_CR36","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1093\/ntr\/ntac073","volume":"24","author":"MS Gades","year":"2022","unstructured":"Gades MS, et al. The role of nicotine and flavor in the abuse potential and appeal of electronic cigarettes for adult current and former cigarette and electronic cigarette users: a systematic review. Nicotine Tob Res. 2022;24(9):1332\u201343.","journal-title":"Nicotine Tob Res"},{"key":"921_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2020.106145","volume":"140","author":"DL Ashley","year":"2020","unstructured":"Ashley DL, et al. E-cigarettes: how can they help smokers quit without addicting a new generation? Prev Med. 2020;140: 106145.","journal-title":"Prev Med"},{"issue":"5","key":"921_CR38","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/ntr\/ntaa190","volume":"23","author":"Z Cahn","year":"2021","unstructured":"Cahn Z, et al. Applying the population health standard to the regulation of electronic nicotine delivery systems. Nicotine Tob Res. 2021;23(5):780\u20139.","journal-title":"Nicotine Tob Res"},{"key":"921_CR39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.yrtph.2017.07.032","volume":"89","author":"P Brossard","year":"2017","unstructured":"Brossard P, et al. Nicotine pharmacokinetic profiles of the Tobacco Heating System 2.2, cigarettes and nicotine gum in Japanese smokers. Regul Toxicol Pharmacol. 2017;89:193\u20139.","journal-title":"Regul Toxicol Pharmacol."},{"issue":"5","key":"921_CR40","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/ntr\/ntv220","volume":"18","author":"P Picavet","year":"2016","unstructured":"Picavet P, et al. Comparison of the pharmacokinetics of nicotine following single and ad libitum use of a tobacco heating system or combustible cigarettes. Nicotine Tob Res. 2016;18(5):557\u201363.","journal-title":"Nicotine Tob Res"},{"key":"921_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108395","volume":"217","author":"NI Goldenson","year":"2020","unstructured":"Goldenson NI, et al. Abuse liability assessment of the JUUL system in four flavors relative to combustible cigarette, nicotine gum and a comparator electronic nicotine delivery system among adult smokers. Drug Alcohol Depend. 2020;217: 108395.","journal-title":"Drug Alcohol Depend"},{"issue":"17","key":"921_CR42","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1007\/s00213-017-4665-y","volume":"234","author":"MF Stiles","year":"2017","unstructured":"Stiles MF, et al. Pharmacodynamic and pharmacokinetic assessment of electronic cigarettes, combustible cigarettes, and nicotine gum: implications for abuse liability. Psychopharmacology. 2017;234(17):2643\u201355.","journal-title":"Psychopharmacology"},{"issue":"7","key":"921_CR43","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00213-018-4904-x","volume":"235","author":"MF Stiles","year":"2018","unstructured":"Stiles MF, et al. Assessment of the abuse liability of three menthol Vuse Solo electronic cigarettes relative to combustible cigarettes and nicotine gum. Psychopharmacology. 2018;235(7):2077\u201386.","journal-title":"Psychopharmacology"},{"issue":"1","key":"921_CR44","doi-asserted-by":"publisher","first-page":"18951","DOI":"10.1038\/s41598-023-45894-7","volume":"13","author":"C Campbell","year":"2023","unstructured":"Campbell C, et al. Abuse liability of two electronic nicotine delivery systems compared with combustible cigarettes and nicotine gum from an open-label randomized crossover study. Sci Rep. 2023;13(1):18951.","journal-title":"Sci Rep"},{"issue":"1","key":"921_CR45","doi-asserted-by":"publisher","first-page":"22080","DOI":"10.1038\/s41598-022-26417-2","volume":"12","author":"C Campbell","year":"2022","unstructured":"Campbell C, et al. Part one: abuse liability of Vuse Solo (G2) electronic nicotine delivery system relative to combustible cigarettes and nicotine gum. Sci Rep. 2022;12(1):22080.","journal-title":"Sci Rep"},{"issue":"11","key":"921_CR46","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1093\/ntr\/nts007","volume":"14","author":"K Fagerstr\u00f6m","year":"2012","unstructured":"Fagerstr\u00f6m K, Eissenberg T. Dependence on tobacco and nicotine products: a case for product-specific assessment. Nicotine Tob Res. 2012;14(11):1382\u201390.","journal-title":"Nicotine Tob Res"},{"issue":"9","key":"921_CR47","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/j.1360-0443.1991.tb01879.x","volume":"86","author":"TF Heatherton","year":"1991","unstructured":"Heatherton TF, et al. The fagerstr\u00f6m test for nicotine dependence: a revision of the fagerstr\u00f6m tolerance questionnaire. Br J Addict. 1991;86(9):1119\u201327.","journal-title":"Br J Addict"},{"issue":"44","key":"921_CR48","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.15585\/mmwr.mm6444a2","volume":"64","author":"Centers for Disease Control and Prevention","year":"2015","unstructured":"Centers for Disease Control and Prevention. Current cigarette smoking among adults-United States, 2005\u20132014. Morb Mortal Wkly Rep. 2015;64(44):1233\u201340.","journal-title":"Morb Mortal Wkly Rep"},{"key":"921_CR49","unstructured":"International Council on Harmonisation, What\u2019s New MedDRA Version 24.1. 2021."},{"issue":"3","key":"921_CR50","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s002130000382","volume":"149","author":"R West","year":"2000","unstructured":"West R, et al. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology. 2000;149(3):198\u2013202.","journal-title":"Psychopharmacology"},{"issue":"3","key":"921_CR51","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/ntr\/ntab183","volume":"24","author":"A Vansickel","year":"2021","unstructured":"Vansickel A, et al. Human abuse liability assessment of tobacco and nicotine products: approaches for meeting current regulatory recommendations. Nicotine Tob Res. 2021;24(3):295\u2013305.","journal-title":"Nicotine Tob Res"},{"issue":"7","key":"921_CR52","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1093\/ntr\/ntab247","volume":"24","author":"J Foulds","year":"2022","unstructured":"Foulds J, et al. Effect of electronic nicotine delivery systems on cigarette abstinence in smokers with no plans to quit: exploratory analysis of a randomized placebo-controlled trial. Nicotine Tob Res. 2022;24(7):955\u201361.","journal-title":"Nicotine Tob Res"},{"issue":"6","key":"921_CR53","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/add.14936","volume":"115","author":"P Hajek","year":"2020","unstructured":"Hajek P, et al. Nicotine delivery and users\u2019 reactions to Juul compared with cigarettes and other e-cigarette products. Addiction. 2020;115(6):1141\u20138.","journal-title":"Addiction"},{"issue":"1","key":"921_CR54","doi-asserted-by":"publisher","first-page":"9037","DOI":"10.1038\/s41598-023-36259-1","volume":"13","author":"S McDermott","year":"2023","unstructured":"McDermott S, et al. An assessment of nicotine pharmacokinetics and subjective effects of the pulze heated tobacco system compared with cigarettes. Sci Rep. 2023;13(1):9037.","journal-title":"Sci Rep"},{"issue":"6","key":"921_CR55","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3390\/toxics11060525","volume":"11","author":"J Vukas","year":"2023","unstructured":"Vukas J, et al. Two different heated tobacco products vs. cigarettes: comparison of nicotine delivery and subjective effects in experienced users. Toxics. 2023;11(6):525.","journal-title":"Toxics"},{"key":"921_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yrtph.2017.08.006","volume":"90","author":"G Jaccard","year":"2017","unstructured":"Jaccard G, et al. Comparative assessment of HPHC yields in the Tobacco Heating System THS22 and commercial cigarettes. Regul Toxicol Pharmacol. 2017;90:1\u20138.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"18","key":"921_CR57","doi-asserted-by":"publisher","first-page":"27051","DOI":"10.1007\/s11356-021-18032-x","volume":"29","author":"T K\u00e4rkel\u00e4","year":"2022","unstructured":"K\u00e4rkel\u00e4 T, Tapper U, Kajolinna T. Comparison of 3R4F cigarette smoke and IQOS heated tobacco product aerosol emissions. Environ Sci Pollut Res Int. 2022;29(18):27051\u201369.","journal-title":"Environ Sci Pollut Res Int"},{"key":"921_CR58","doi-asserted-by":"publisher","first-page":"121","DOI":"10.12688\/f1000research.74718.1","volume":"11","author":"L Malt","year":"2022","unstructured":"Malt L, et al. The product science of electrically heated tobacco products: a narrative review of the scientific literature. F1000 Research. 2022;11:121.","journal-title":"F1000 Research"},{"issue":"2","key":"921_CR59","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1016\/j.yrtph.2016.10.016","volume":"8","author":"JP Schaller","year":"2016","unstructured":"Schaller JP, et al. Evaluation of the Tobacco Heating System 2.2 Part 3: Influence of the tobacco blend on the formation of harmful and potentially harmful constituents of the Tobacco Heating System 22 aerosol. Regul Toxicol Pharmacol. 2016;8(2):S48-s58.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"5","key":"921_CR60","volume":"16","author":"S Cordery","year":"2024","unstructured":"Cordery S, et al. The product science of electrically heated tobacco products: an updated narrative review of the scientific literature. Cureus. 2024;16(5): e61223.","journal-title":"Cureus"},{"key":"921_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2022.105510","volume":"86","author":"F Chapman","year":"2022","unstructured":"Chapman F, et al. Multiple endpoint in vitro toxicity assessment of a prototype heated tobacco product indicates substantially reduced effects compared to those of combustible cigarette. Toxicol In Vitro. 2022;86: 105510.","journal-title":"Toxicol In Vitro"},{"issue":"3","key":"921_CR62","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/ntr\/ntaa135","volume":"23","author":"N Gale","year":"2021","unstructured":"Gale N, et al. Changes in biomarkers of exposure on switching from a conventional cigarette to the glo tobacco heating product: a randomized controlled ambulatory study. Nicotine Tob Res. 2021;23(3):584\u201391.","journal-title":"Nicotine Tob Res"},{"issue":"8","key":"921_CR63","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s11739-021-02798-6","volume":"16","author":"N Gale","year":"2021","unstructured":"Gale N, et al. Changes in biomarkers after 180 days of tobacco heating product use: a randomised trial. Intern Emerg Med. 2021;16(8):2201\u201312.","journal-title":"Intern Emerg Med"},{"issue":"9","key":"921_CR64","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/ntr\/nty104","volume":"21","author":"N Gale","year":"2019","unstructured":"Gale N, et al. Changes in biomarkers of exposure on switching from a conventional cigarette to tobacco heating products: a randomized, controlled study in healthy japanese subjects. Nicotine Tob Res. 2019;21(9):1220\u20137.","journal-title":"Nicotine Tob Res"},{"issue":"7","key":"921_CR65","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s11739-022-03062-1","volume":"17","author":"N Gale","year":"2022","unstructured":"Gale N, et al. Changes in biomarkers of exposure and biomarkers of potential harm after 360 days in smokers who either continue to smoke, switch to a tobacco heating product or quit smoking. Intern Emerg Med. 2022;17(7):2017\u201330.","journal-title":"Intern Emerg Med"},{"issue":"2","key":"921_CR66","doi-asserted-by":"publisher","first-page":"S139","DOI":"10.1016\/j.yrtph.2016.11.003","volume":"81","author":"C Haziza","year":"2016","unstructured":"Haziza C, et al. Evaluation of the tobacco heating system 22 part 8: 5-day randomized reduced exposure clinical study in Poland. Regul Toxicol Pharmacol. 2016;81(2):S139-s150.","journal-title":"Regul Toxicol Pharmacol"},{"key":"921_CR67","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.dib.2016.11.047","volume":"10","author":"C Haziza","year":"2017","unstructured":"Haziza C, et al. Biomarker of exposure level data set in smokers switching from conventional cigarettes to tobacco heating system 2.2, continuing smoking or abstaining from smoking for 5 days. Data Brief. 2017;10:283\u201393.","journal-title":"Data Brief"},{"issue":"2","key":"921_CR68","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/ntr\/ntw287","volume":"20","author":"F L\u00fcdicke","year":"2018","unstructured":"L\u00fcdicke F, et al. Effects of switching to the tobacco heating system 2.2 menthol, smoking abstinence, or continued cigarette smoking on biomarkers of exposure: a randomized, controlled, open-label, multicenter study in sequential confinement and ambulatory settings (part 1). Nicotine Tob Res. 2018;20(2):161\u201372.","journal-title":"Nicotine Tob Res"},{"issue":"4","key":"921_CR69","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/ntr\/ntz084","volume":"22","author":"C Haziza","year":"2020","unstructured":"Haziza C, et al. Favorable changes in biomarkers of potential harm to reduce the adverse health effects of smoking in smokers switching to the menthol tobacco heating system 2.2 for 3 months (Part 2). Nicotine Tob Res. 2020;22(4):549\u201359.","journal-title":"Nicotine Tob Res"},{"issue":"11","key":"921_CR70","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1158\/1055-9965.EPI-18-0915","volume":"28","author":"F L\u00fcdicke","year":"2019","unstructured":"L\u00fcdicke F, et al. Effects of switching to a heat-not-burn tobacco product on biologically relevant biomarkers to assess a candidate modified risk tobacco product: a randomized trial. Cancer Epidemiol Biomarkers Prev. 2019;28(11):1934\u201343.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"921_CR71","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/ntr\/ntx028","volume":"20","author":"F L\u00fcdicke","year":"2018","unstructured":"L\u00fcdicke F, et al. Effects of switching to the menthol tobacco heating system 2.2, smoking abstinence, or continued cigarette smoking on clinically relevant risk markers: a randomized, controlled, open-label, multicenter study in sequential confinement and ambulatory settings (part 2). Nicotine Tob Res. 2018;20(2):173\u201382.","journal-title":"Nicotine Tob Res"},{"issue":"7","key":"921_CR72","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/ntr\/ntab014","volume":"23","author":"C Sakaguchi","year":"2021","unstructured":"Sakaguchi C, et al. Differences in levels of biomarkers of potential harm among users of a heat-not-burn tobacco product, cigarette smokers, and never-smokers in japan: a post-marketing observational study. Nicotine Tob Res. 2021;23(7):1143\u201352.","journal-title":"Nicotine Tob Res"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00921-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-024-00921-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00921-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T14:06:26Z","timestamp":1731074786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-024-00921-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["921"],"URL":"https:\/\/doi.org\/10.1007\/s13318-024-00921-4","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"assertion":[{"value":"3 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was funded by RAI Services Company, a wholly owned subsidiary of Reynolds American Inc., which is an indirect, wholly owned subsidiary of British American Tobacco plc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors are current employees of RAI Services Company. This study was funded by RAI Services Company. RAI Services Company is a wholly owned subsidiary of Reynolds American Inc., which is an indirect, wholly owned sub-sidiary of British American Tobacco p.l.c.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The applicable data generated or analyzed during this study are included in this manuscript (and its supplementary Materials). Additional datasets access for this study is administered through an internal Data Sharing Committee on reasonable request following completion of a data sharing request form and if applicable, a Data Access Agreement. Requests for data sharing in the first instance should be emailed to the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Prior to study commencement, the final protocol, the Informed Consent Form (ICF), and all other pertinent study documents were approved (approval date: 30Apr2021) by Advarra Institutional Review Board (Columbia, MD, USA), Organization number: 0000635; Registration number: 00000971). The study was conducted in accordance with the US Code of Federal Regulations (CFR) governing Protection of Human Subjects (21 CFR 50), all other applicable fed-eral regulations, and under the principles of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Guideline for Good Clinical Practice E6(R2).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all subjects involved in the research prior to starting any of the research-related activities.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization, S.A.B. and P.M.; methodology, S.A.B. and P.M.; formal analysis, M.N.K.; investigation, K.P. and M.N.K.; resources, S.A.B.; writing\u2014original draft preparation, M.N.K.; writing\u2014review and editing, M.N.K., P.M., K.P., and S.A.B.; visualization, M.N.K; supervision, P.M. and S.A.B.; project administration, K.P.; funding acquisition, S.A.B. All authors have read and agreed to the published version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"The authors acknowledge the expert assistance of the clinical study site (Alliance for Multispecialty Research, Knox-ville, TN USA), the contract research organization (NCGS, Charleston, NC USA), and the bioanalytical laboratory (Celerion Global Bioanalytical Services, Lincoln, NE, USA) in conducting the study. The authors also thank GL Prasad (Prasad Scientific Consulting LLC) and Ian M. Fearon (whatIF? Consulting Ltd) for assisting with manuscript preparation; Kristen G. Jordan, Megan J. Whelen, Nathan Gale, and Brian M. Keyser for critical review of the manuscript and significant contributions during manuscript preparation; Jason Hong for scientific study oversight and study design, Jenna M. Guynn for assistance with study design; Gregory P. Tarleton, PharmD, MD for providing medical expertise to ensure subject safety; Eckhardt Schmidt for bioanalytical data oversight; Peter Chen for statistical support, and Jason Henstock and Jeff Coffield for maintaining the study Trial Master File and managing other study-related documenta-tion.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgments"}}]}}